MENLO PARK, Calif.--(BUSINESS WIRE)--Alydia Health, a commercial-stage medical device company focused on making childbirth safer for all mothers, today announced that industry veteran Paul Praino has joined the company as Vice President of Sales. Praino will lead Alydia Health’s expanding sales efforts for the Jada System, an innovative device designed to encourage normal contraction of the uterus to rapidly stop excessive bleeding after childbirth.
“Paul is an experienced commercial sales leader who is skilled at hiring, developing and motivating his team to meet the scalability needs of high-growth organizations and deliver sales results,” said Rob Binney, Chief Executive Officer of Alydia Health. “As we prepare to join Organon and build a high-performing medical device sales organization, we believe Paul is the right person to lead the acceleration of the Jada System launch to more hospitals and patients across the U.S.”
Alydia Health’s U.S. commercial organization is rapidly growing with seven additional representatives also joining the company. This team has robust experience navigating the hospital purchasing and contracting process, as well as deep strength in procedure training and market development. Alydia Health and Merck recently entered into a definitive agreement pursuant to which, after the intended Merck spinoff, Organon will acquire Alydia Health.
Praino brings nearly 15 years of experience and success working at every level of medical device sales at premier companies including Access Closure, Acclarent and Intersect ENT. He joins Alydia Health after most recently serving as Global Vice President, Sales at Intersect ENT where his accomplishments included delivering record revenue and growth for key products, leading the commercial integration of Intersect ENT’s acquisition of Fiagon, and numerous awards throughout his years at the company. Praino received his Master of Arts & Science in education from Mercy College and his Bachelor of Arts in education from Plattsburgh State University of New York.
About Alydia Health
Founded in 2010 with a vision to make childbirth safer for all mothers, Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding – a challenging condition to manage and a growing problem in the U.S. and globally. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.1
Alydia Health’s device, the Jada System, is designed to encourage normal contraction of the uterus to rapidly stop excessive bleeding after childbirth. Alydia received 510(k) clearance (marketing authorization) from the FDA for the Jada System in August 2020 based on results from the company’s pivotal PEARLE IDE Study. For more information, visit www.alydiahealth.com and follow the company on Twitter at @AlydiaHealth and on LinkedIn.
1 Widmer M et al. "Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth." N Engl J Med 2018; 379:743-752